Nucleix's Bladder EpiCheck™, Urine Test for Monitoring Bladder Cancer, Chosen as Standard-of-Care by Radboud University Medical Center

REHOVOT, Israel, Jan. 30, 2019 /PRNewswire/ -- Nucleix Ltd., a leading cancer detection and screening company, announced today that Radboud University Medical Center (UMC) in Nijmegen, the Netherlands has chosen to add the Company's Bladder EpiCheck™, a urine test for the monitoring of...

from PR Newswire: https://prn.to/2RroZe9